Physician profile
Grace Kim
NPI 1083634323
$13,822.19
in general payments reported to CMS, 2019-2025
48 companies · $1,655 in 2025
The $1,655 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,728 · 2020: $1,617 · 2021: $1,869 · 2022: $2,150 · 2023: $2,405 · 2024: $2,398 · 2025: $1,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,444 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,443.76 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,644.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $2,400.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,507.73 | 2019-2025 | Repatha, Tepezza, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $641.76 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $583.52 | 2019-2025 | Jardiance |
| Corcept Therapeutics | $563.68 | 2019-2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $541.07 | 2019-2025 | |
| Dexcom, INC. | $487.08 | 2022-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $424.10 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $389.24 | 2019-2024 | Farxiga |
| Alexion Pharmaceuticals, INC. | $350.45 | 2020-2024 | Strensiq |
| Xeris Pharmaceuticals, INC. | $326.42 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Madrigal Pharmaceuticals | $273.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbott Laboratories | $250.84 | 2019-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $192.47 | 2022-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $192.46 | 2019-2021 | |
| Amarin Pharma, INC. | $185.12 | 2020-2021 | |
| Horizon Therapeutics Plc | $167.48 | 2019-2023 | Tepezza |
| Abbvie INC. | $152.49 | 2019-2025 | |
| Mannkind Corporation | $140.65 | 2019-2021 | |
| Ibsa Pharma INC. | $128.86 | 2019-2022 | |
| Medtronic, INC. | $123.79 | 2021-2023 | Minimed 780g |
| Shire North American Group INC | $87.09 | 2019 | |
| Vivus LLC | $82.87 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $81.34 | 2019-2020 | |
| Kyowa Kirin, INC. | $79.04 | 2023-2025 | Crysvita |
| Becton, Dickinson and Company | $65.52 | 2021 | |
| Currax Pharmaceuticals LLC | $60.77 | 2023-2025 | Contrave |
| Embecta Corp. | $56.15 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Tandem Diabetes Care, INC. | $55.80 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Rgh Enterprises LLC | $52.94 | 2023-2025 | |
| Ascensia Diabetes Care US INC. | $49.36 | 2024 | |
| Beta Bionics, INC. | $49.26 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Astellas Pharma US INC | $48.36 | 2023 | Veozah |
| Ultragenyx Pharmaceutical INC. | $44.18 | 2022-2024 | Crysvita |
| Recordati_rare_diseases_inc. | $44.00 | 2023-2025 | Isturisa, Signifor Lar |
| Cequr Corporation | $37.74 | 2022-2023 | Cequr Simplicity |
| Medtronic Minimed, INC. | $36.51 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $34.91 | 2019 | |
| Insulet Corporation | $29.72 | 2019 | |
| Ascendis Pharma Endocrinology INC | $28.86 | 2023 | |
| Bigfoot Biomedical INC | $28.67 | 2022 | |
| Acella Pharmaceuticals, LLC | $20.53 | 2025 | NP Thyroid 60 |
| Regeneron Healthcare Solutions, INC. | $19.98 | 2019 | |
| Companion Medical, INC. | $17.37 | 2019 | |
| Lifescan, INC. | $14.83 | 2019 | |
| Alfasigma USA, INC. | $14.58 | 2021 | |
| Glaxosmithkline, LLC. | $14.41 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.